Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Nonalcoholic fatty liver disease.
Paredes AH, Torres DM, Harrison SA. Paredes AH, et al. Clin Liver Dis. 2012 May;16(2):397-419. doi: 10.1016/j.cld.2012.03.005. Clin Liver Dis. 2012. PMID: 22541706 Review.
Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.
Harrison SA, Dennis A, Fiore MM, Kelly MD, Kelly CJ, Paredes AH, Whitehead JM, Neubauer S, Traber PG, Banerjee R. Harrison SA, et al. Among authors: paredes ah. PLoS One. 2018 Sep 7;13(9):e0203054. doi: 10.1371/journal.pone.0203054. eCollection 2018. PLoS One. 2018. PMID: 30192782 Free PMC article. Clinical Trial.
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, Ling L, DePaoli AM. Harrison SA, et al. Among authors: paredes ah. Hepatology. 2020 Apr;71(4):1198-1212. doi: 10.1002/hep.30590. Epub 2019 Apr 10. Hepatology. 2020. PMID: 30805949 Free PMC article.
Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exercise.
Paredes AH, Torres DM, Harrison SA. Paredes AH, et al. Clin Liver Dis (Hoboken). 2012 Sep 25;1(4):117-118. doi: 10.1002/cld.63. eCollection 2012 Sep. Clin Liver Dis (Hoboken). 2012. PMID: 31186865 Free PMC article. Review. No abstract available.
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Harrison SA, et al. Among authors: paredes ah. Gastroenterology. 2020 Aug 8:S0016-5085(20)35018-6. doi: 10.1053/j.gastro.2020.08.004. Online ahead of print. Gastroenterology. 2020. PMID: 32781086 Free article.
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R. Harrison SA, et al. Among authors: paredes ah. Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5. Lancet. 2018. PMID: 29519502 Clinical Trial.
Drug-induced liver injury in 2007.
Norris W, Paredes AH, Lewis JH. Norris W, et al. Curr Opin Gastroenterol. 2008 May;24(3):287-97. doi: 10.1097/MOG.0b013e3282f9764b. Curr Opin Gastroenterol. 2008. PMID: 18408456 Review.
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME, Trotter JF, Abdelmalek MF, Paredes AH, Connelly MA, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Harrison SA. Rinella ME, et al. Among authors: paredes ah. J Hepatol. 2019 Apr;70(4):735-744. doi: 10.1016/j.jhep.2018.11.032. Epub 2018 Dec 8. J Hepatol. 2019. PMID: 30529590 Free article.
Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
Kar S, Paglialunga S, Jaycox SH, Islam R, Paredes AH. Kar S, et al. Among authors: paredes ah. PLoS One. 2019 Jul 10;14(7):e0217263. doi: 10.1371/journal.pone.0217263. eCollection 2019. PLoS One. 2019. PMID: 31291245 Free PMC article.
23 results
Jump to page
Feedback